Science and Research

Our Pipeline  

Beginning with patients’ needs, we build our pipeline by identifying the most promising science and collaborate with leading teams around the globe to accelerate innovation. Our oncology R&D activities are focused on translating science into curative or transformative potential treatments by targeting tumor vulnerabilities and through novel strategies that leverage the power of innate immunity. 

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

Investigational Therapy

Platform

Investigational Indication

Phase

Cabozantinib*

Targeted therapy

Metastatic castration-​resistant prostate cancer (JP)

Phase 3

Targeted therapy

2L metastatic non-small cell lung cancer (JP)

Phase 3

Description

Tyrosine kinase inhibitor including MET/AXL/VEGFR 

Additional information: 

Cabozantinib is being developed in Japan in collaboration with Exelixis. 

Ixazomib*

Proteasome inhibitor

Maint. newly diagnosed multiple myeloma post- stem cell transplant (US, EU)

Phase 3

Proteasome inhibitor

Maint. newly diagnosed multiple myeloma without stem cell transplant (US, EU, CN)

Phase 3

Description: 

Proteasome inhibitor 

Mobocertinib*

Targeted therapy

2L EGFR Exon20 insertion non-small cell lung cancer (CN)

Filed

Targeted therapy

1L EGFR Exon20 insertion non-small cell lung cancer (US, EU, GEM)

Phase 3

Description:

Oral EGFR Exon20 tyrosine kinase inhibitor

Ponatinib*

Targeted therapy

FL Ph+ acute lymphocytic leukemia (US)

Phase 3

Description: 

BCR-ABL inhibitor 

Additional information:

Takeda shares development rights with Incyte Corp. (Europe, Turkey and Israel) and Otsuka Pharm. (Asia Pacific territories). 

Relugolix* (TAK-385)

Small molecule

Prostate cancer (JP, Asian countries)

Phase 3

Description: 

GnRH Antagonist 

Additional information: 

Relugolix is being developed in Japan and Asian countries in collaboration with Myovant Sciences, Inc. 

Niraparib*

Targeted therapy

Triple-negative breast cancer

Phase 3

Description:
PARP 1/2 inhibitor
Additional information:
Niraparib is being developed in collaboration with GSK. Takeda has development and commercialization rights for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea and Taiwan.

Modakafusp Alfa (TAK-573)

I-O cold-to-hot

Multiple myeloma

Phase 1/2

I-O cold-to-hot

Solid tumors

Phase 1/2

Description:

Immune targeting attenuated cytokine

Additional information:

Modakafusp alfa (TAK-573) was licensed from Teva Pharmaceuticals.

Subasumstat (TAK-981)

I-O cold-to-hot

Solid tumors

Phase 1/2

I-O cold-to-hot

Non-Hodgkin lymphoma

Phase 1/2

I-O cold-to-hot

Multiple myeloma

Phase 1/2

Description: 

SUMOylation inhibitor 

TAK-007

I-O redirected immunity

B-cell malignancies

Phase 2^

Description: 

CD19 CAR NK 

Additional information: 

TAK-007 is being developed in collaboration with The University of Texas MD Anderson Cancer Center.  

TAK-186

I-O redirected immunity

Solid tumors

Phase 1/2

Description: 

EGFR x CD3 targeting COBRA (COnditional Bispecific Redirected Activation) T cell engager immunotherapy

TAK-102

I-O redirected immunity

Solid tumors

Phase 1

Description: 

GPC3 targeted CAR-T 

Additional information: 

TAK-102 was licensed from Noile-Immune Biotech.  

TAK-103

I-O redirected immunity

Solid tumors

Phase 1

Description:

Mesothelin targeted CAR-T

Additional information:

TAK-103 was licensed from Noile-Immune Biotech.

TAK-500

I-O cold-to-hot

Solid tumors

Phase 1

Description:

Targeted STING agonist

TAK-676

I-O cold-to-hot

Solid tumors

Phase 1

Description: 

STING agonist 

TAK-940

I-O redirected immunity

B-cell malignancies

Phase 1

Description: 

CD19-1XX CAR-T 

Additional information: 

TAK-940 is being developed in collaboration with Memorial Sloan Kettering Cancer Center.  

TAK-280

I-O redirected immunity

Solid tumors

Phase 1/2

Description:
B7-H3 x CD3 targeting COBRA (COnditional Bispecific Redirected Activation) T cell engager immunotherapy

*Marketed products have received approval in one or more jurisdictions.
^Study actively recruiting.
All programs have global development rights unless otherwise noted.
GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets

Investors

To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page

Explore More

Newsroom

Keep up on the latest Oncology news by visiting our newsroom

Partnership Strategy

We believe the best way to achieve our aspiration to cure cancer is by working together

R&D Approach

Decades of leadership in Oncology with a diverse and robust pipeline